Showing results (191-200 of 831) with videos related to

Sort By:
Pageof 84
British Journal of Haematology|June 6, 2017
Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort studyPaolo Strati, Sameer A Parikh, Kari G Chaffee, et al.
Cancer|May 22, 2007
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemiaTait D Shanafelt, Thomas Lin, Susan M Geyer, et al.
British Journal of Haematology|November 21, 2007
Susceptibility genes and B-chronic lymphocytic leukaemiaSusan L Slager, Neil E Kay, Zachary S Fredericksen, et al.
Leukemia & Lymphoma|August 3, 2012
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximabClive S Zent, Wenting Wu, Deborah A Bowen, et al.
Blood|August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinibXin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
Cancer|August 15, 2013
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopeniaPaolo Strati, William Wierda, Jan Burger, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
Leukemia Research|May 26, 2004
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemiaSrdan Verstovsek, Francis J Giles, Susan O'Brien, et al.
Cancer|February 29, 2012
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapyHagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, et al.
Cancer|March 20, 2002
Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimenMary A Weiser, Susan O'Brien, Deborah A Thomas, et al.
Pageof 84